Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Martin

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
The Lancet. Rheumatology|January 30, 2024
Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 studyDominique Farge, Séverine Loisel, Matthieu Resche-Rigon, et al.
The Lancet. Rheumatology|March 29, 2025
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?Marc Scherlinger, Gaetane Nocturne, Marko Radic, et al.
Bulletin Du Cancer|November 28, 2017
[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Grégory Pugnet, Christina Castilla-Llorente, Mathieu Puyade, et al.
Lupus Science & Medicine|July 4, 2020
Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestationsAurore Meyer, Aurélien Guffroy, Gilles Blaison, et al.
Rheumatology (Oxford, England)|May 11, 2021
Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patientsDan Levy, Benoit Nespola, Margherita Giannini, et al.
Journal of Medicinal Chemistry|March 6, 2008
Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseasesStefano Crosignani, Patrick Page, Marc Missotten, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 16, 2023
Refining Incidence and Characteristics of Inflammatory Myopathies: A Quadruple-Source Capture-Recapture Survey Using the 2017 European League Against Rheumatism/American College of Rheumatology Classification CriteriaLéa Debrut, Margherita Giannini, Delphine Klein, et al.
Autoimmunity Reviews|August 18, 2020
Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective studyPhilippe Mertz, Jean-François Kleinmann, Marc Lambert, et al.
Clinical and Experimental Rheumatology|May 17, 2022
Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patientsImane Abouyahya, Sophie I E Liem, Zahir Amoura, et al.
Plos One|September 13, 2016
Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and LupusDoua F Azzouz, Gabriel V Martin, Fanny Arnoux, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
The Lancet. Rheumatology|January 30, 2024
Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 studyDominique Farge, Séverine Loisel, Matthieu Resche-Rigon, et al.
The Lancet. Rheumatology|March 29, 2025
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?Marc Scherlinger, Gaetane Nocturne, Marko Radic, et al.
Bulletin Du Cancer|November 28, 2017
[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Grégory Pugnet, Christina Castilla-Llorente, Mathieu Puyade, et al.
Lupus Science & Medicine|July 4, 2020
Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestationsAurore Meyer, Aurélien Guffroy, Gilles Blaison, et al.
Rheumatology (Oxford, England)|May 11, 2021
Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patientsDan Levy, Benoit Nespola, Margherita Giannini, et al.
Journal of Medicinal Chemistry|March 6, 2008
Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseasesStefano Crosignani, Patrick Page, Marc Missotten, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 16, 2023
Refining Incidence and Characteristics of Inflammatory Myopathies: A Quadruple-Source Capture-Recapture Survey Using the 2017 European League Against Rheumatism/American College of Rheumatology Classification CriteriaLéa Debrut, Margherita Giannini, Delphine Klein, et al.
Autoimmunity Reviews|August 18, 2020
Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective studyPhilippe Mertz, Jean-François Kleinmann, Marc Lambert, et al.
Clinical and Experimental Rheumatology|May 17, 2022
Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patientsImane Abouyahya, Sophie I E Liem, Zahir Amoura, et al.
Plos One|September 13, 2016
Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and LupusDoua F Azzouz, Gabriel V Martin, Fanny Arnoux, et al.
Pageof 15